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Phthalates are used in large quantities as soft-
eners in many plastic products, paint, glue,
putty, pharmaceutical products and cosmetics
(Agency for Toxic Substances and Disease
Registry 2001, 2002; Schettler 2006). About
5,000–6,000 tons of phthalates, including
di(2-ethylhexyl) phthalate (DEHP), are used
per year in Sweden. Typically, phthalates are
not chemically bound to the product matrix
and may thus migrate and permit extensive
exposure. People may be exposed in the work
environment, via food from plastic containers
and via inhalation of dust in domestic environ-
ments (Wormuth et al. 2006). Dermal expo-
sure via clothes and cosmetics may also occur.
Small population groups may be exposed via
medical equipment—for example, to DEHP
migrating from plastic tubing used for treat-
ment of premature infants (Calafat et al.
2004a; Weuve et al. 2006). 
Numerous studies have reported reproduc-
tive effects, including reduced sperm produc-
tion and shortened anogenital distance (AGD)
in laboratory animals, and concern exists that
phthalates may induce antiandrogenic and/or
proestrogenic effects in humans (Andrade
et al. 2006; Borch et al. 2006; Fabjan et al.
2006; Gray et al. 2006; Hauser 2006; Hauser
et al. 2006; Pflieger-Bruss et al. 2004).
Developmental defects in male rat pups, simi-
lar to those seen in humans in a syndrome
termed testicular dysgenesis syndrome (TDS),
have been documented after dosing pregnant
dams with di-n-butyl phthalate (DBP), DEHP,
or butyl benzyl phthalate (BBzP) (Sharpe
2005). Signaling pathways affected by phtha-
lates are currently under intense study (Ge et al.
2007; Hallmark et al. 2007; Howdeshell et al.
2007; Lahousse et al. 2006; Liu et al. 2005;
Mahood et al. 2006; Sharpe 2006). 
Phthalate diesters are metabolized, and
most studies of human exposure report con-
centrations of phthalate metabolites in urine.
In the body, hydrolytic monoester metabolites
can undergo phase 1 (e.g., oxidation) and
phase 2 (e.g., glucuronidation) metabolism
(Koch et al. 2003b). In biological samples,
such as blood or serum, milk, or other com-
plex biological samples, contaminating phtha-
late diesters may be hydrolyzed by esterases to
their respective hydrolytic monoesters during
sampling, storage, and analysis (Kato et al.
2004). However, oxidized monoester metabo-
lites cannot easily be ascribed to contamina-
tion (Koch et al. 2003b, 2004, 2005, 2006b). 
Recent U.S. studies summarize data from
> 2,500 individuals participating in the
National Health and Nutrition Examination
Survey (NHANES) [Centers for Disease
Control and Prevention (CDC) 2005; Silva
et al. 2004a]. In general, higher concentra-
tions of urinary metabolites were found in
women than in men. This pattern was also
seen in a German study (Koch et al. 2003b),
and other studies show ethnic differences
(CDC 2005; Silva et al. 2004a). 
The toxicologic proﬁle of phthalates and
perhaps a higher prevalence of exposure
among women suggest that pregnant women,
fetuses, and newborns could be highly sensi-
tive risk groups. In the present study, per-
formed in 2001 at the request of the Swedish
Environmental Protection Agency, we mea-
sured several common phthalates and their
metabolites in human milk, blood or serum,
and urine. The main objectives of this study
were to evaluate whether multimatrix bio-
monitoring of phthalates in women of child-
bearing ages is feasible, and to identify the
most suitable biological matrix for health-
related environmental monitoring of risk
groups in the general population.
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BACKGROUND: Phthalates may pose a risk for perinatal developmental effects. An important question
relates to the choice of suitable biological matrices for assessing exposure during this period. 
OBJECTIVES: This study was designed to measure the concentrations of phthalate diesters or their
metabolites in breast milk, blood or serum, and urine and to evaluate their suitability for assessing
perinatal exposure to phthalates.
METHODS: In 2001, 2–3 weeks after delivery, 42 Swedish primipara provided breast milk, blood,
and urine samples at home. Special care was taken to minimize contamination with phthalates (e.g.,
use of a special breast milk pump, heat treatment of glassware and needles, addition of phosphoric
acid). 
RESULTS: Phthalate diesters and metabolites in milk and blood or serum, if detected, were present
at concentrations close to the limit of detection. By contrast, most phthalate metabolites were
detectable in urine at concentrations comparable to those from the general population in the
United States and in Germany. No correlations existed between urine concentrations and those
found in milk or blood/serum for single phthalate metabolites. Our data are at odds with a previous
study documenting frequent detection and comparatively high concentrations of phthalate metabo-
lites in Finnish and Danish mothers’ milk.
CONCLUSIONS: Concentrations of phthalate metabolites in urine are more informative than those in
milk or serum. Furthermore, collection of milk or blood may be associated with discomfort and
potential technical problems such as contamination (unless oxidative metabolites are measured).
Although urine is a suitable matrix for health-related phthalate monitoring, urinary concentrations
in nursing mothers cannot be used to estimate exposure to phthalates through milk ingestion by
breast-fed infants.
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Study group. Of about 130 consecutive
Swedish women approached in connection
with a normal delivery at Lund University
Hospital in southern Sweden, 68 were willing
to participate in the study. Of those, 42
(median age, 29; range, 23–39 years) partici-
pated; the dropout was caused by logistic
problems in sampling, postdelivery tiredness,
or scarcity of breast milk. Two women were
smokers, 35 were nonsmokers, and ﬁve were
ex-smokers. 
The project was approved by the Ethical
Committee at Lund University and by the
Institutional Review Board at the CDC.
Participants gave written informed consent.
Interview. The mothers were visited 4–5
times in their homes by a nurse. At one of the
visits, the mothers were interviewed, and at
the others only sampling took place. The
mothers were interviewed about factors that
might have contributed to their exposure to
phthalates: the delivery (including medica-
tion), body weights of mother and baby, the
mother’s height, age, education, family, occu-
pation, place of residence, renovation of the
home, car, exercise, lifestyle habits (use of cof-
fee, tea, cigarettes, snuff), use and brands of
cosmetic and hygiene products (perfume,
antiperspirant, skin lotion, toothpaste, deter-
gents), health, and medication.
Six (14%) mothers reported a chronic dis-
ease (allergy, eczema, treated hypothyroidism).
Nine (21%) mothers had suffered some kind
of pregnancy problems. Twenty-seven (64%)
of the mothers had > 3 years of university edu-
cation, ﬁve (12%) had 1–3 years of university
education, eight (19%) had 3–4 years of high
school education, and the remaining two
mothers (5%) had 1–2 years of high school
education. Twenty-four mothers lived in a pri-
vate house and 18 in apartments; 26 of the
mothers reported that their home had been
renovated since they moved there. The babies
were 25 girls and 17 boys. Their birth weight
(mean ± SD) was 3,586 ± 450 g. 
Sampling. Breast milk. All 42 mothers
gave milk samples. At the time of breast milk
sampling, the babies were 14–20 days of age
(median, 17 days). The mothers were
instructed not to use skin care products
before sampling.
The milk samples were collected by using
a pump made of polycarbonate. The pump
consisted of a piston in cylinder housing
(Amningspump; Artaplast, Tyresö, Sweden).
The rubber seal of the piston of the commer-
cial pump was found to contain high concen-
trations of DEHP. Even when the seal was
replaced by a phthalate-free one, high levels of
DEHP appeared in the blank samples.
Hence, new pumps with fluoroelastomer
(black Viton; Norton Verneret, Cavaillon,
France) tubing seal were used. The pump was
rinsed with ethanol before use. The milk was
transferred to preheated (400°C for 2 hr)
laboratory glass bottles with glass stoppers.
The samples were stored in a refrigerator
(4°C) for a couple of hours. After collection
of 50–100 mL milk, phosphoric acid was
added and the samples were stored in a freezer
(–80°C) until transferred to the laboratory at
the Swedish Environmental Research
Institute Ltd. (IVL) and analyzed.
Blood. Thirty-six of the mothers gave
blood samples, collected 1 week after milk
sampling. Blood was taken with a stainless
steel needle from a cubital vein and allowed to
drop into preheated glass test tubes. Five milli-
liters of blood were mixed with 10,000 IE of
heparin. Phosphoric acid was added and the
tube openings were covered by clean alu-
minium foil to protect the sample from con-
tacts with the polytetraethyleneﬂuoride screw
caps. The samples were stored in a freezer
(–20°C) until transferred to IVL and analyzed.
Further, untreated blood was centrifuged.
Serum was collected by using phthalate-free
tubing and a heated pipette, mixed with phos-
phoric acid, and stored in a freezer.
Urine. Thirty-eight of the mothers pro-
vided urine samples at the time of blood sam-
pling. About 100 mL urine was collected in a
heated glass beaker, and 5 mL was frozen
(–80°C) in a tube and transferred to the labo-
ratory at the CDC.
Additional measures to control for cont-
amination. Chemicals added to the samples,
heparin and ethylenediaminetetraacetic acid,
were checked by gas chromatography–mass
spectrometry (GC-MS) before use. Nitrile
plastic gloves, containing negligible amounts
of phthalates (assessed by GC-MS) were used
in this study when collecting body fluids.
Milk and blood samples were acidified with
phosphoric acid (1 M; 125 µL/mL) about
1 hr after the collection (Calafat et al. 2004b;
David and Sandra 2001) to avoid enzymatic
hydrolysis of the phthalate diesters. The sam-
ples were stored in a freezer at the University
Hospital of Lund.
Measurement of phthalate diesters in
blood and milk. The phthalate diesters were
measured at IVL. Because of the ubiquitous
presence of these compounds, all solvents
(Rathburn Chemical Ltd., Peeblesshire,
Scotland) used were checked, and the clean-
ing procedure for equipment of glass and
metal (and inorganic salts) included heating
at 400°C for 4 hr. At least two blanks were
analyzed along with each batch of samples to
monitor background concentrations of phtha-
late diesters.
The blood samples (10 mL) were thawed
and diluted with ultrapure water. Surrogate
standards were added and the sample was
extracted twice with 5mL hexane:MTBE (1:1)
and once with 3 mL hexane. The extract was
concentrated and cleaned up on an amino
propylene column (International Sorbent
Technology, Ltd., Tucson, AZ, USA). 
The milk samples (10 mL) were thawed
and extracted according to a method described
earlier (David and Sandra 2001). Brieﬂy, the
sample was extracted with pentane:acetone
and hexane:MTBE after addition of sodium
chloride and ultrapure water. The acetone was
washed away with water, and the extract was
subjected to cleanup using gel permeation
chromatography [5 mL/min pentane:MTBE
(1:1), PL-gel column, 300 × 25 mm; 10 µm,
50 Å, Polymer Laboratories Varian, Inc.,
Amherst, MA, USA] and the amino propylene
column. 
We analyzed the extracts using GC-MS
with a mass selective detector in selected ion
monitoring mode (Agilent 6890N; Agilent
Technologies Inc., Santa Clara, CA, USA).
The analytes were identiﬁed by their a) char-
acteristic retention time, b) one quantiﬁcation
ion, and, in most cases, c) one confirmation
ion to increase specificity. The calibration
standard was a certified standard mixture of
six phthalate esters (Ultra Scientific; J.T.
Baker, Pillipsburgh, NJ, USA). The mixture
contained dimethyl phthalate, diethyl phtha-
late (DEP), DBP, BBzP, DEHP, and di-n-
octyl phthalate (DOP). The commercial
isomeric mixtures di-isononyl phthalate
(DINP) and di-isodecyl phthalate (DIDP)
were kindly supplied bv Perstorp Oxo AB
(Stenungsund, Sweden). The limits of detec-
tion (LODs) ranged from 0.1 to 3.0 ng/mL.
Quantiﬁcation was based on the internal stan-
dards, and the reported concentrations were
corrected for the recovery of those standards.
The recovery rate according to surrogate
standards was 66 ± 11% for the milk samples
and 58 ± 15% blood samples. The results of
the spiked control samples, analyzed in paral-
lel with the samples, are presented in Table 1.
All reported values were recovery corrected
according to the surrogate standards. The pre-
cision was determined to 20% at the concen-
trations detected in the samples. A calculation
of the uncertainty in the measurement
(Ellison et al. 2000) results in an uncertainty
of 19% in the measurement.
Measurement of phthalate metabolites in
serum, milk, and urine. Phthalate metabolites
were measured in urine, breast milk, and serum
at the CDC. The analytic methods involved the
enzymatic deconjugation of the phthalate
metabolites from their glucuronidated form,
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Table 1. Relative recovery (% of added amount) of
phthalates spiked in milk and blood samples. 
DEP DBP BBzP DEHP DOP
Milk 104 86 88 97 77
Blood 95 98 108 103 100
The results are adjusted according to the surrogate
standard.automated solid-phase extraction, separation
with high performance liquid chromatography,
and detection by isotope-dilution tandem mass
spectrometry (Calafat et al. 2004b; Kato et al.
2004; Silva et al. 2004b). The LODs were in
the low nanogram per milliter range; 1 mL of
sample was used for the analysis. Each analytic
run consisted of 50 samples [2 quality control
(QC) materials of high concentration, 2 QC
materials of low concentration, 5 reagent
blanks, and 41 unknown samples]. We ana-
lyzed the QC samples along with unknown
samples to monitor for accuracy and precision.
QC samples were evaluated according to modi-
ﬁed Westgard statistical probability rules.
Statistical analysis. For univariate associa-
tions between the continuous variables, we
used the Spearman correlation test (rs =
Spearman correlation coefficient) from
SigmaStat for Windows (version 3.5; Systat
Software Inc. San Jose, CA, USA). For con-
centrations < LOD, unless stated otherwise,
we imputed a value equal to half the LOD for
the calculations. p-Values < 0.05 were consid-
ered statistically signiﬁcant.
We used multivariate modeling and
analysis to explore possible correlations
between concentrations of individual phtha-
lates, their metabolites, and interview vari-
ables. We used principal component and
partial least squares (PLS) analyses as per-
formed by the statistical package Simca-P
10.0 (Umetrics AB, Umeå, Sweden). The
PLS method was used as described previously
(Wold et al. 1984) and is suited for identiﬁca-
tion and evaluation of systematic variation in
complex data sets. 
Results
Tables 2–5 summarize the concentrations of
phthalate diesters and phthalate metabolites
measured in several biological media (blood
or serum, breast milk, urine), as well as the
number of samples giving results above the
LOD. Most blood or serum and milk samples
had phthalate and phthalate metabolite
concentrations below the LOD, but all urine
samples had detectable concentrations of
most metabolites. No blood or milk sample
contained detectable concentrations of DIDP
or DINP.
The urinary concentrations of oxidized
metabolites of DEHP [mono(2-ethyl-5-oxo-
hexyl) phthalate (mEOHP; rs = 0.30, p =
0.06) and mono(2-ethyl-5-hydroxyhexyl)
phthalate (mEHHP; rs = 0.47, p = 0.003)]
correlated with the concentrations of the
hydrolytic monoester metabolite mono(2-
ethylhexyl) phthalate (mEHP), suggesting that
these three metabolites reflect DEHP expo-
sure. Although the concentrations of mEHHP
and mEOHP in urine were higher than the
concentrations of mEHP, these oxidative
metabolites were not detected in serum or
milk. By contrast, mEHP was detected in a
small percentage of milk and serum samples
(Tables 2 and 3). The range of urine concen-
trations was smaller for the DEHP metabolites
than for mono-n-butyl phthalate (mBP) and
monoethyl phthalate (mEP). 
Except for one sample exhibiting a high
concentration of DEHP in blood (129 ng/mL),
most blood concentrations were close to or
below the LOD. The high blood concentration
of DEHP was not matched by a high concen-
tration of DEHP metabolites in serum or urine
from the same woman, suggesting that con-
tamination may have affected this analysis.
With this exception, our blood DEHP and
serum mEHP results agree with previously
reported serum concentrations of DEHP (< 14
ng/mL) and mEHP (< 5 ng/mL) from four
individuals (Takatori et al. 2004). 
Concentrations of phthalates and phtha-
late metabolites in milk (n = 42) were close to
or below the LOD, except for one sample
exhibiting a high concentration (305 ng/mL)
of DEHP. The woman with high DEHP in
milk was not the one with high DEHP in
blood, and her mEHP concentration in milk
was low (unfortunately, we had no blood or
urine data from this woman). In general, the
milk concentrations of metabolites were lower
than the corresponding parent compounds
concentrations in milk. We did not observe
significant correlations between parent com-
pounds and the corresponding metabolites in
milk (DEHP–mEHP: rs = 0.023, n = 42;
DBP–mBP: rs = –0.12, n = 42). For DBP, the
lack of correlation may be attributable to the
low number of samples with concentrations
above the LOD. If only samples above the
LOD (n = 12) were included in the analysis,
we observed a negative signiﬁcant correlation
between DBP and mBP in milk (rs = –0.63;
p = 0.024). 
In a search for correlations between con-
centrations in different matrices, we drew sev-
eral plots, but no obvious patterns could be
discerned. However, there was an apparent
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Table 2. Concentrations of phthalates and their metabolites in milk (ng/mL). 
Parent compounds Metabolites
Milk DEP DBP BBzP DEHP DOP mBP mBzP mEHP mEP miBP
No. of samples 42 42 42 42 42 42 42 42 42 42
No. > LOD 8 12 41 39 10 11 3 16 1 2
Minimum 0.22 1.5 0.06 0.45 0.24 0.54 0.50 0.49 0.50 0.52
Maximum 1.45 20 4.4 305 11 5.7 4.4 6.5 2.5 2.1
Median 0.22 1.5 0.49 9.0 0.24 0.54 0.50 0.49
75th percentile 0.22 3.1 0.92 13 0.24 1.3 0.50 1.7 0.50 0.52
Mean 0.30 2.8 0.75 17 1.1 1.2 0.64 1.3
SD 0.24 3.4 0.80 47 2.3 1.3 0.63 1.3
LOD 0.44 3.0 0.12 0.90 0.47 1.1 1.0 0.98 1.0 1.0
Values < LOD were set to LOD/2. The DEHP oxidative metabolites, MEHHP and MEOHP, were not detected in any of the
samples analyzed.
Table 3. Concentrations of phthalates and metabolites in blood and serum (ng/mL).
Blood parent compounds Serum metabolites
Blood and serum DEP DBP BBzP DEHP DOP mBP mEHP mEP miBP
No. of samples 36 36 36 36 36 36 36 36 36
No. > LOD 29 25 29 17 7 17 6 7 3
Minimum 0.066 0.21 0.050 0.50 0.70 0.54 0.49 0.50 0.50
Maximum 1.1 9.1 1.4 129 10.0 20 4.5 14 11
Median 0.24 0.78 0.25 0.50 0.70 0.54 0.49 0.50 0.50
75th percentile 0.37 1.3 0.36 2.7 0.70 1.9 0.49 0.50 0.50
Mean 0.31 1.2 0.29 5.9 1.5 1.8 0.77 1.2 0.87
SD 0.26 1.6 0.27 21 2.1 3.3 0.80 2.3 1.8
LOD 0.13 0.43 0.10 1.0 1.4 1.1 0.98 1.0 1.0
Values < LOD were set to LOD/2. The DEHP oxidative metabolites, MEHHP and MEOHP, were not detected in any of the
samples analyzed.
Table 4. Concentrations of phthalate metabolites in urine (ng/mL).
Urine mBP mBzP mCPP mEHHP mEHP mEOHP mEP mMP miBP
No. of samples 38 38 38 38 38 38 38 38 38
No. > LOD 38 38 25 38 38 37 37 20 34
Minimum 5.1 2.2 0.5 1.4 2.9 0.54 0.50 0.50 0.52
Maximum 198 38 9.1 126 57 83 761 15 130
Median 46 13 1.5 15 9 11 35 1.2 16
75th percentile 68 20 2.5 29 17 24 80 2.8 30
Mean 53 16 1.9 25 13 19 84 2.3 21
SD 45 10 1.7 27 10 19 141 3.0 24
LOD 1.1 1.0 1.0 0.95 0.98 1.1 1.0 1.0 1.0
Abbreviations: mCPP, mono(3-carboxypropyl) phthalate; mMP, monomethyl phthalate. Values < LOD were set to LOD/2. correlation between urine mEP and serum
mEP (7 values > LOD) (rs = 0.48, p < 0.003,
n = 36), but no correlation with blood DEP
(29 values > LOD), so the biological signiﬁ-
cance of this correlation is uncertain. After
removal of an apparent outlier, there was still
a signiﬁcant correlation (rs = 0.41, p = 0.014,
n = 35). It is possible that this correlation
reflects the urinary excretion of mostly
unconjugated mEP, whereas variable conjuga-
tion rates (due to polymorphisms in the phase
2 glucuronidation reaction enzyme, uridine
5´-diphosphate glucoronosyltransferase) may
have eroded correlations for other monoester
metabolites that are generally excreted in their
conjugated form. Women having detectable
milk concentrations of mEHP exhibited a
slightly elevated, although not statistically sig-
nificant, ratio between mEHP/(mEOHP +
mEHHP) concentrations in urine.
We performed a multivariate analysis
using the analytic results and the individual
data collected in the interviews. The complete
data set and selected subsets did not reveal
any significant correlations between concen-
trations of individual phthalate diesters, their
metabolites, or any of the exposure variables
recorded, except those described above for
urinary DEHP metabolites and for mEP in
urine and serum. In several models, we
observed weak positive associations between
age and the concentrations of a few metabo-
lites in milk and urine. 
Discussion
The present study population is small, though
carefully recruited. It might be argued that
the study group was not representative for the
average Swedish woman. The participants
were selected from a three times larger group
of potential participants, and selected individ-
uals had a relatively high level of education.
This may partially relate to the fact that they
lived in a small university town and might
have been more interested than average
women in the study results. However, we do
not think that this selection has seriously
biased our results. Also, we made great efforts
to avoid contamination with and degradation
of phthalates. This included the use of a spe-
cial milk pump, heat treatment of glassware
and needles, and addition of phosphoric acid.
The urinary concentrations of phthalate
metabolites in the Swedish mothers studied
here are in the ranges previously reported for
other population groups living in Germany
and the United States (CDC 2005; Koch
et al. 2003a; Silva et al. 2004a; Swan et al.
2005) (Table 6). The strong correlations seen
between the urinary concentrations of the
three DEHP metabolites were expected and
argue against contamination in the urine sam-
ples. The distribution of the various metabo-
lites may thus reflect common exposures of
humans. In a group of 85 Germans, the cal-
culated daily intake of DEHP (based on uri-
nary metabolite concentrations, shown here
in Table 6) exceeded the European tolerable
daily intake value, based on reproductive toxi-
city [CSTEE (European Scientiﬁc Committee
on Toxicity, Ecotoxicity and Environment)
1998], for 12% of the individuals (Koch et al.
2003a). Similarly, on the basis of similar uri-
nary data, Koch et al. (2006a) concluded that
about one third of 2- to 4-year-old German
children had an intake of DBP that exceeded
the tolerable daily intake. 
Somewhat worrisome perhaps are our data
on the metabolites of DBP, DEHP, and BBzP,
which have been found to produce a TDS-like
syndrome in rats (Hallmark et al. 2007;
McKinnell et al. 2005; Sharpe 2005). The
metabolites of these phthalates were detected
(Table 6) at slightly higher median urinary con-
centrations among this group of Swedish moth-
ers than those found in one study correlating
phthalate exposure in the United States to a
shortened AGD (Swan et al. 2005). Toxic
effects of mixtures of antiandrogens may exhibit
additivity (Howdeshell et al. 2007; Metzdorff
et al. 2007), and the sum of medians for the
DBP, DEHP, and BBzP metabolites were 378
nmoles/L in the Swedish samples and 182
nmoles/L in the U.S. samples. However, the
sum of all medians in Table 6 was higher in the
U.S. samples (861 nmoles/L) than in the
Swedish samples (646 nmoles/L). Only concen-
trations of mEP, mBP, monobenzyl phthalate
(mBzP), and mono-iso-butyl phthalate (miBP)
correlated with shortened AGD in the U.S.
human study (Swan et al. 2005), and their
sums of medians were 759 nmoles/L in the
U.S. samples and 512 nmoles/L in the Swedish
samples. However, the fact that prenatal/late
pregnancy (the U.S. study) and postnatal (the
Swedish study) samples were used for these
analyses hampers the comparison because preg-
nancy alters pharmacokinetic parameters
(Anderson 2005). 
The blood and serum data are more difﬁ-
cult to interpret. We observed no obvious
correlations between these concentrations and
concentrations of the metabolites in urine,
even for the oxidized metabolites, which
should not have been affected by potential
contamination (Kato et al. 2004). The urine
and blood samples were collected up to
1 week after the milk samples, but urine con-
centrations are quite reproducible from day to
day (Hoppin et al. 2002), so variability in uri-
nary concentrations can hardly explain the
lack of correlation. Therefore, it seems that
having many serum concentrations below the
LOD and the fact that the methodology used
did not permit accurate analysis of prevailing
low concentrations were important factors.
Other factors that may erode correlations
include hydrolysis of phthalate diesters intro-
duced as contaminants during handling of the
samples. Even dust in ambient air might be a
factor of importance that is hard to control
for in a domestic environment and under
conditions employed to collect the samples in
our study. Thus, considering the limitations
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Table 5. Concentrations of phthalate metabolites in urine (µg/g creatinine).
Urine mBP mBzP mCPP mEHHP mEHP mEOHP mEP mMP miBP
No. of samples 38 38 38 38 38 38 38 38 38
No. > LOD 38 38 25 38 38 37 37 20 34
Minimum 18 4.5 0.5 5.1 4.6 3.0 5.5 0.3 1.1
Maximum 191 63 16 86 74 57 862 12 110
Median 50 17 1.6 24 15 15 39 1.9 15
75th percentile 68 27 2.7 33 24 24 119 2.8 23
Mean 56 20 2.4 25 18 18 101 2.5 21
SD 37 13 2.6 18 14 13 160 2.5 21
Abbreviations: mCPP, mono(3-carboxypropyl) phthalate; mMP, monomethyl phthalate. Values < LOD were set to LOD/2. 
Table 6. Comparison of urinary concentrations (ng/mL) by percentile in the present study (Sweden), a U.S.
study on ADG, the 1999–2000 NHANES, and a German study. 
Sweden USA ADGa USA NHANESb Germanyc
Metabolite 50th 75th 50th 75th 50th 75th 50th
Monoester 
mBPd 45.5 68 13.5 30.9 30.0 59.5 181
mBzPd 13.2 20 8.3 23.5 16.0 35.8 21.0
mCPP 1.5 2.5 2.1 3.6
mEPd 35 80 128.4 437 174 425 90.2
miBPd 16.4 30 2.5 5.1
mMP 1.2 2.8 0.7 3.2
DEHP
mEHHP 14.6 29 11.4 20.1 46.8
mEHP 9.0 17 3.3 9.0 3.00 7.00 10.3
mEOHP 11.3 24 11.1 19.0 36.5
Abbreviations: mCPP, mono(3-carboxypropyl) phthalate; mMP, monomethyl phthalate.
aSwan et al. (2005). bSilva et al. (2004a). cKoch et al. (2003b). dCorrelated with AGD (Swan et al. 2005).in sensitivity of the analytic procedures, the
potential contamination issues, as well as the
discomfort associated with the blood sam-
pling procedure, blood or serum sampling
cannot be recommended for surveying phtha-
late exposure in the general population. Even
surveying small targeted groups of susceptible
individuals by using blood or serum samples
might turn out to be much more complicated
than using urine.
Collecting human milk samples was labo-
rious, time consuming, and associated with
potential contamination problems. It also
required special sampling equipment and pro-
cedures. Furthermore, the milk samples obvi-
ously contained too low concentrations of
phthalates and metabolites to permit a more
comprehensive and detailed discussion of
actual concentrations in this matrix. Despite
the time difference in sampling urine and
milk, our data do not support the notion that
the mothers’ urinary concentrations can be
used for assessing exposure through breast
milk. However, if correlations do exist
between urine and milk concentrations, and
can be documented, the use of urine samples
would greatly facilitate the study of exposure
of breast-fed children. 
Some data are available on levels of phtha-
lates in human milk. Infant exposure to
DEHP or mEHP via milk has been reviewed
(Latini et al. 2004). Furthermore, analytic
methods for measuring several phthalate
metabolites in milk are available (Main et al.
2006; Mortensen et al. 2005), and data from
a small number of pooled samples (Calafat
et al. 2004b) and from two Danish/Finnish
studies involving the analysis of individual
human samples exist (Main et al. 2006;
Mortensen et al. 2005). The recent Danish/
Finnish studies (Main et al. 2006; Mortensen
et al. 2005) report higher concentrations of
some phthalate metabolites in human milk
than we found. Speciﬁcally, the median con-
centrations for mBP were 4.3 and 12 µg/L,
for mBzP were 0.9 and 1.3 µg/L, for mEHP
were 9.5 and 13 µg/L, and for mEP were 0.93
and 0.97 µg/L, in Denmark and Finland
respectively (Main et al. 2006). Considering
the similarities in lifestyle and demographics
between Sweden and the other two Nordic
countries, these differences are surprising.
Only a few of the Swedish samples exhibited
values above the LOD (∼ 1.0 ng/mL) for
these metabolites (Table 2), although several
of the concentrations reported by Main et al.
(2006) should have been possible to detect
with our analytic procedure. It has been spec-
ulated that contaminations may have influ-
enced the results (Kavlock et al. 2006), and
our data tend to support this. Also, in a recent
review (Frederiksen et al. 2007), the same
concentration figures are presented in
nanograms per liter and not in nanograms per
milliliter. In addition, the Danish/Finish sam-
ples were collected prospectively and earlier
(1997–2001) than our samples, and temporal
concentration trends of phthalates in the
three Nordic countries are unknown. A closer
analysis of factors that might explain these
observed differences is thus urgent.
In conclusion, the results of this study
indicate that sampling of breast milk or blood
and analysis for phthalates is not a straightfor-
ward approach that can be recommended for
surveillance of infants’ exposure to phthalates.
Samples might easily be contaminated with
the ubiquitous phthalate diesters. Our data
also indicate that the analytic methods used,
having LODs generally in the low parts per
billion, were not sensitive enough for ade-
quate quantification of common phthalates
and their metabolites in human blood, serum,
or milk in the Swedish population. In con-
trast, measuring phthalate metabolites in
urine gives more informative results. The
metabolite urinary concentrations in this
group of Swedish women were similar to
those reported among German and U.S. pop-
ulations. However, it is evident that this study
cannot answer the question whether analysis
of maternal urine can be used to estimate
exposure to phthalates through milk ingestion
by breast-fed children. Additional research to
address phthalate exposure in Swedish popu-
lations and in relation to AGD and other
TDS-related end points is warranted. 
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